Villanueva, A. Hepatocellular Carcinoma. N. Engl. J. Med. 380, 1450-1462 (2019).
Kudo, M. et al. Lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma: a phase 3 randomized non-inferiority study. Lancet 391, 1163-1173 (2018).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of the incidence and mortality worldwide for 36 cancers in 185 countries. CA Krebs J. Clin. 71: 209-249 (2021).
Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, JM Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149, 1226-1239 (2015).
Llovet, JM et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
Finn, RS et al. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894-1905 (2020).
Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechn. 34, 631-633 (2016).
Zhu, AX et al. SEARCH: a randomized, double-blind, placebo-controlled phase III study of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33: 559-566 (2015).
Matsuki, M. et al. Lenvatinib inhibits angiogenesis and signaling pathways of tumor fibroblast growth factor in human hepatocellular carcinoma models. Krebs Med. 7, 2641-2653 (2018).
Wagle, M.-C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in several cancers. NPJ Exactly. Oncol. 2, 7 (2018).
Pirker, R. et al. EGFR expression as a predictor of survival with first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13: 33-42 (2012).
Kimura, T. et al. The immunomodulatory activity of lenvatinib contributes to the antitumor activity in the hepatocellular carcinoma model Hepa1-6. Cancer Sci. 109, 3993-4002 (2018).
Li, E., Lin, L., Chen, CW & Ou, DL Mouse models for immunotherapy in hepatocellular carcinoma. Cancer Diseases (Basel) 11, 1800 (2019).
Keng, VW et al. A conditional transposon-based insertion mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechn. 27: 264-274 (2009).
Er, H. et al. The platelet-derived growth factor requires an epidermal growth factor receptor to activate the kinases of the p21-activated kinase family. J. Biol. Chem. 276: 26741-26744 (2001).
Lee, S.-W. et al. The EGFR-Pak signaling pathway selectively regulates macropinocytosis induced by glutamine deficiency. Dev. Cell 50: 381-392 (2019).
Vaseva, AV et al. The breakdown of MYC induced by KRAS suppression is antagonized by a MEK5-ERK5 compensation mechanism. Krebszelle 34, 807-822 (2018).
Duncan, JS et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple negative breast cancer. Cell 149: 307-321 (2012).
Lito, P. et al. The alleviation of the profound feedback inhibition of mitogenic signaling by RAF inhibitors weakens their activity in BRAFV600E melanoma. Krebszelle 22, 668-682 (2012).
Kosoff, RE et al. Pak2 inhibits endomitosis during megakaryopoiesis and changes the organization of the cytoskeleton. Blood 125, 2995-3005 (2015).
Kobayashi, S. et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of the signal transduction of the mutated epidermal growth factor receptor. Krebs Res. 66, 11389-11398 (2006).
Philip, PA et al. Phase II trial of erlotinib (OSI-774) in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 23: 6657-6663 (2005).
Chan, SL et al. New use of an old marker: serial α-fetoprotein measurement to predict radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27: 446-452 (2009).
Llovet, JM & Lencioni, R. mRECIST for HCC: Performance and New Refinements. J. Hepatol. 72, 288-306 (2020).
Ding, X. et al. Genomic and epigenomic characteristics of primary and recurrent hepatocellular carcinomas. Gastroenterology 157, 1630-1645 (2019).
Cremolini, C. et al. Early tumor shrinkage and response depth predict the long-term outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab: results of the Phase III TRIBE study by the Gruppo Oncologico del Nord Ovest. Ann. Oncol. 26: 1188-1194 (2015).
Love, MI, Huber, W. & Anders, S. Moderated Estimation of Folding Change and Dispersion for RNA-seq Data Using DESeq2. Genom Biol. 15, 550 (2014).
Jin, H. et al. Regulator of the calcineurin-1 gene isoform 4, which is downregulated in hepatocellular carcinoma, prevents the proliferation, migration and invasive activity of cancer cells and the metastasis of orthotopic tumors by inhibiting the nuclear translocation of NFAT1. Gastroenterology 153, 799-811 (2017).
Mazières, J. et al. Assessment of EGFR Protein Expression by Immunohistochemistry Using the H-Score and the Magnification Rule: Re-Analysis of the SATURN Study. Lung Cancer 82, 231-237 (2013).
Sun, C. et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
Wang, L. et al. High-throughput screenings with functional genes and compounds identify targets for senescence induction in cancer. Cell Rep. 21, 773-783 (2017).
Schuhmacher, M. et al. The human B-cell line transcription program in response to Myc. Nucleic Acids Res. 29, 397-406 (2001).
Wang, C. et al. Inducing and exploiting weak points for the treatment of liver cancer. Nature 574, 268-272 (2019).
World Medical Association. Declaration of the World Medical Association of Helsinki. Ethical principles for medical research on humans. Bull. World Health Organ. 79: 373-374 (2001).